West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. Asian Pacific Journal of Cancer Prevention 1513-7368 21 1 2020 01 01 Promising Anticancer Effect of Aurisin A Against the Human Lung Cancer A549 Cell Line 49 54 88887 10.31557/APJCP.2020.21.1.49 EN Parichart Boueroy Faculty of Public Health, Kasetsart University Chalermphrakiat Sakon Nakhon Province Campus, Sakon Nakhon,Thailand. Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. Thidarut Boonmars Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. Cholangiocarcinoma Research Institute, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. Somdej Kanokmedhakul Natural Products Research Unit, Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Khon Kaen University, Khon Kaen, Thailand. Sorujsiri Chareonsudjai Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen , Thailand. Ratsami Lekphrom Natural Products Research Unit, Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Khon Kaen University, Khon Kaen, Thailand. Suphachira Srichangwang Research Administration Division, Khon Kaen University, Khon Kaen, Thailand. Journal Article 2019 03 04 Objective: To investigate the anticancer effect of aurisin A and the underlying mechanisms of its action on the human lung cancer A549 cell line. Methods: Cell viability was determined by sulforhodamine B (SRB) assay, while cell cycle distribution and apoptosis were measured by flow cytometry. The molecular underlying mechanisms of anti-cancer properties of aurisin A was determined by western blot analysis. Results: Aurisin A exerts its anticancer effects by inhibiting cell growth (p<0.001), increasing the proportion of cells at the G0/G1 phase (p<0.001), and decreasing the expression of cyclin D (p<0.05) and cyclin-dependent kinase 4 (Cdk-4) (p<0.001). Nuclear morphological changes were observed in aurisin A-treated cells, demonstrated by a dose-dependent increase in the number of apoptosis cells (p<0.001). After aurisin A treatment, B-cell lymphoma 2 (Bcl-2) was down-regulated (p<0.05), cleaved caspase-3 was up-regulated (p<0.05). In addition, aurisin A inhibits migration of cancer cells in a dose-dependent manner (p<0.001) and decreases the expression of epidermal growth factor receptor (EGFR) (p<0.05) and phosphorylated p38 (pp38) (p<0.05). Conclusion: These results indicated that in-vitro treatment of aurisin A against this human lung cancer cell line inhibits cell proliferation and migration, and induces apoptosis and cell-cycle arrest.  Aurisin A is a promising anticancer agent for use against human lung cancer.<br />   https://journal.waocp.org/article_88887_e5bebb81453faf82ba289d023c6b3fd8.pdf